Veterinary Vaccine Market Size & Share Analysis 2032 According to a newly published market research report by 24LifeSciences, the global veterinary vaccine market was valued at USD 10.54 billion in 2024 and is projected to reach USD 17.48 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period 2025–2031. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7433/veterinary-vaccine-market

https://www.databridgemarketresearch.com/reports/global-bacillus-calmette-guerin-bcg-vaccine-market

https://www.databridgemarketresearch.com/reports/global-aquaculture-vaccine-market

Human Injection Flu Vaccine Market Market Outlook: Opportunities & Trends According to a newly published market research report by 24LifeSciences, Global Human Injection Flu Vaccine Market was valued at USD 7351 million in 2024 and is projected to reach USD 10760 million by 2031, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period 2024–2031. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3442/human-injection-flu-vaccine-market

BCG Vaccine Market to Grow at 3.3% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global Bacille Calmette-Guerin vaccine market was valued at USD 73.4 million in 2024 and is projected to reach USD 91.7 million by 2031, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2025-2031. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3756/bacille-calmette-guerin-vaccine-market

23-Valent Pneumococcal Vaccine Market Analysis 2034 | Regional Trends According to a newly published market research report by 24LifeSciences, global 23-valent pneumococcal polysaccharide vaccine market was valued at USD 1012 million in 2023 and is projected to reach USD 2083 million by 2030, growing at a compound annual growth rate (CAGR) of 11.1% during the forecast period from 2024 to 2030. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3857/valent-pneumococcal-polysaccharide-vaccine--global-outlook-and-market

BCG Vaccine Market to Grow at 3.3% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global Bacille Calmette-Guerin vaccine market was valued at USD 73.4 million in 2024 and is projected to reach USD 91.7 million by 2031, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2025-2031. Bacille Calmette-Gurin (BCG) vaccine, a live-attenuated strain derived from Mycobacterium bovis, remains the world's most widely administered vaccine for tuberculosis prevention and stands as a cornerstone in global immunization programs. Its primary role involves protecting infants and young children in regions with high TB prevalence from severe forms of the disease, including military TB and TB meningitis. While its efficacy against pulmonary TB in adults shows limitations, its established protective benefits for pediatric populations ensure its continued relevance in public health strategies worldwide. Beyond TB prevention, the vaccine has gained significant therapeutic importance in oncology, particularly for the treatment of non-muscle-invasive bladder cancer, representing a vital secondary application that diversifies its market value. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3756/bacille-calmette-guerin-vaccine-market

Top 10 Companies Leading the Non-Replicating mRNA Vaccine Market Growth According to a newly published market research report by 24LifeSciences, global non-replicating mRNA vaccine market was valued at USD 1.34 billion in 2024 and is projected to reach USD 2.32 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.9% during the forecast period 2025-2032. Non-replicating mRNA vaccines represent a novel class of therapeutics based on messenger RNA technology, characterized by mRNA that does not replicate within the recipient's body. These vaccines work by delivering mRNA encoding specific antigens to human cells, prompting them to produce protein fragments that subsequently stimulate the immune system to generate both antibody production and T-cell activation. Due to their non-replicating nature, these vaccines are considered highly safe as they cannot cause infection or disease. The technology demonstrated significant advantages during the COVID-19 pandemic, establishing itself as a platform capable of rapid response to emerging health threats. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5190/non-replicating-mrna-vaccine-market

Global Pertussis Vaccine Market to Grow at a CAGR of 3.8% by 2032 According to a newly published market research report by 24LifeSciences, global pertussis vaccine market was valued at USD 4,917 million in 2024 and is projected to reach USD 6,341 million by 2031, growing at a compound annual growth rate (CAGR) of 3.8% during the forecast period 2025-2031. Pertussis vaccines, which protect against whooping cough caused by the Bordetella pertussis bacterium, are critical components of global immunization programs. These vaccines are available as whole-cell (wP) and more commonly used acellular (aP) formulations, with the latter offering a refined safety profile. Their established role in preventing severe respiratory illness, particularly in vulnerable infant populations, continues to underpin their public health importance and drive consistent market demand across both pediatric and adult vaccination schedules. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7394/pertussis-vaccine-market

https://www.databridgemarketresearch.com/reports/global-pediatric-vaccine-market